Support 100 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
11 May 2020updated 06 Oct 2020 9:45am

President of Madagascar dismisses WHO concerns over coronavirus tonic

By Rohan Banerjee

Andry Rajoelina, the president of Madagascar, has hit back at criticism from the World Health Organisation (WHO) over COVID-Organics infusion – the herb-based “remedy” developed by the country’s scientists to treat coronavirus.

The tonic, which resembles tea, is derived from artemisia, a plant with proven efficacy in treating malaria, as well as several other herbs native to the island.

Rajoelina, speaking to Radio France International (RFI), accused the WHO of “underestimating” the intelligence of African people. He said: “If it wasn’t Madagascar, and if it was a European country that had actually discovered this remedy, would there be so much doubt? I don’t think so.”  

The WHO has expressed concerns regarding the tonic’s curative credentials, as it has not been clinically tested outside of Madagascar. Despite this, several African countries, including Niger and Guinea-Bissau, have signed up for shipments of the of the potion, which launched in April. “No country or organisation will keep us from going forward,” Rajoelina told RFI.

Sign up for The New Statesman’s newsletters Tick the boxes of the newsletters you would like to receive. Quick and essential guide to domestic and global politics from the New Statesman's politics team. The New Statesman’s global affairs newsletter, every Monday and Friday. The best of the New Statesman, delivered to your inbox every weekday morning. A handy, three-minute glance at the week ahead in companies, markets, regulation and investment, landing in your inbox every Monday morning. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A weekly dig into the New Statesman’s archive of over 100 years of stellar and influential journalism, sent each Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy